W W W .Bio Visio N .Co M New Products Added in 2020

Total Page:16

File Type:pdf, Size:1020Kb

W W W .Bio Visio N .Co M New Products Added in 2020 New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus IgM/IgG Antibody Detection Card K1463 25 Tests Mycoplasma Staining Kit K1482 2 ml, 10 ml Coronavirus Rapid RT-qPCR Detection Kit K1461 100 Rxns ToxOut™ Phase Extraction Endotoxin Removal Kit K2507 10 Columns Cyclic-di-GMP Assay Kit K1483 100 assays Phenylalanine Ammonia-Lyase Activity Assay Kit (F) K2055 100 assays DNA Bisulfite Conversion Kit I K1478 50 Rxns, 200 Rxns Phytase Activity Assay Kit (F) K2054 100 assays 50 Preps, DNA Bisulfite Conversion Kit II K1479 200 Preps MagPure™ 96-well Plasmid Purification Kit K1477 1 Plate, 4 Plates DNA Library Prep Kit for IIlumina Sequencing K1475 12 Rxns Plasminogen (PLG) Assay Kit (C) K2064 100 assays 50 Preps, 250 Plasminogen Activator Inhibitor-1 Activity Assay Kit (C) K2040 100 assays Dried Body Fluids DNA Purification Kit K1464 Preps PNGase F Deglycosylation Kit K2061 100 assays 50 Preps, Eye, Nose & Swabs gDNA Purification Kit K1467 200 assays, 250 Preps EZQuant™ RNA Quantification Kit I K1480 1000 assays 200assays, Firefly Luciferase Assay Kit K2062 200 assays, 1000 assays EZQuant™ RNA Quantification Kit II K1481 1000 assays PicoProbe™ Fructose-1,6-Bisphosphate Assay Kit (F) K2036 100 assays 50 Preps, Saliva DNA Purification Kit K1468 Furin Inhibitor Screening Kit (F) K2069 100 assays 250 Preps 50 Preps, SARS-CoV-2 S1 Protein-ACE2 Binding Inhibitor Screening Kit K2050 100 assays Gel and PCR DNA Purification kit K1455 250 Preps Sialyltransferase Activity Assay Kit (F) K2048 100 assays Beta-Glucan Assay Kit (F) K2068 100 assays 50 Preps, Sperm DNA Purification Kit K1465 Glutamine Synthetase Activity Assay Kit (C) K2056 100 assays 250 Preps 50 Preps, Glutamine Synthetase Inhibitor Screening Kit (F) K2059 100 assays Stool DNA Purification Kit K1474 250 Preps 50 Preps, Hair, Nails & Feathers DNA Purification Kit K1469 250 Preps Sucrose Phosphorylase Activity Assay Kit (C) K2034 100 assays High Sensitivity Carbohydrate Assay Kit (C) K2049 100 assays EZCell™ Thiol Detection Kit K2063 100 assays Viral RNA Extraction Kit for Respiratory Specimens K1462 50 Rxns, 250 Rxns * C: Colorimetric; F: Fluorometric Antibodies Product Name Cat. No. Size Product Name Cat. No. Size Anti-ACE2 Antibody A2072 100 µg Anti-BRCA1 Antibody A2157 100 µl Anti-ADAR1 Antibody A2035 100 µl Anti-BSG Antibody A2101 100 µl recMAb™ Anti-ANGPT2 Antibody A2244 100 µl Anti-C1S (Sutimlimab), Humanized Antibody A2205 100 µg Anti-ANGPTL3 (Evinacumab), Human IgG4 Antibody A2171 100 µg Anti-C5 (Eculizumab), Humanized Antibody A2138 100 µg Anti-ANPEP Antibody A2100 100 µg CA19-9 Antibody (Clone# 121SLE), Carrier-Free A2227 100 µg Anti-ATG5 (KO Validated) Antibody A2119 100 µl Anti-CALCA/CALCB (Eptinezumab), Humanized Antibody A2217 100 µg Anti-ATGL Antibody (Clone# ARC1192) A2238 100 µl Anti-Canine Coronavirus (Capture) Antibody A2069 100 µg Anti-ATM Antibody A2211 100 µl Anti-Canine Coronavirus (Self-pair) Antibody A2068 100 µg recMAb™ Anti-ATRX/RAD54 Antibody A2216 100 µg Anti-Canine Coronavirus Polyclonal Antibody A2070 100 µg recMAb™ Anti-B7-H4 Antibody A2215 100 µg Anti-Caspase-3 (Active) Biotinylated Antibody A2116 30 µl, 100 µl www.biovision.com 155 S. Milpitas Blvd, Milpitas, CA 95035 T: 408-493-1800 F: 408-493-1801 Toll Free: 800-891-9699 (US Only) Antibodies Product Name Cat. No. Size Product Name Cat. No. Size Anti-CCR5 (Leronlimab), Humanized Antibody A2181 100 µg Anti-H3R2me1 Antibody A2030 100 µl Anti-CCR8 Rabbit Monoclonal Antibody A2135 100 µl Anti-H3R2me2(asym) Antibody A2025 100 µl Anti-CD137 recMAb™ Antibody A2192 100 µg Anti-H3R2me2(sym) Antibody A2022 100 µl Anti-CD19 (Inebilizumab), Humanized Antibody A2173 100 µg Anti-H3R8me1 Antibody A2045 100 µl Anti-CD19/CD3ε (Blinatumomab), Bispecific Antibody A2225 100 µg Anti-H3R8me2(asym) Antibody A2047 100 µl Anti-CD20 (Obinutuzumab), Humanized Antibody A2180 100 µg Anti-H3R8me2(sym) Antibody A2046 100 µl Anti-CD20 (Ofatumumab), Human IgG1 Antibody A2172 100 µg Anti-H4K5me1 Antibody A2057 100 µl Anti-CD209 recMAb™ Antibody A2193 100 µg Anti-H4K79ac Antibody A2059 100 µl Anti-CD22 (Inotuzumab Ozogamicin), Humanized Antibody A2179 100 µg Anti-H4R3me1 Antibody A2021 100 µl Anti-CD30 (Brentuximab Vedotin), Chimeric Antibody A2177 100 µg Anti-H4R3me2(asym) Antibody A2023 100 µl Anti-CD31 Antibody A2027 100 µl Anti-H4R3me2(sym) Antibody A2024 100 µl Anti-CD38 (Daratumumab), Human IgG1 Antibody A2151 100 µg Anti-HDAC1 (KO Validated) Antibody A2121 100 µl Anti-CD4 (Ibalizumab), Humanized Antibody A2251 100 µg Anti-HER2 (Pertuzumab), Humanized Antibody A2111 100 µg Anti-CD6 (Itolizumab), Humanized Antibody A2164 100 µg Anti-HER2/ErbB2 Antibody A2212 100 µl Anti-CD79B (Polatuzumab Vedotin), Humanized Antibody A2178 100 µg Anti-HIST1H1C K16ac Antibody A2052 100 µl Anti-CD79B recMAb™ Antibody A2196 100 µg Anti-HIST1H1C K62ac Antibody A2071 100 µl Anti-CDK7 Antibody A2039 100 µl Anti-HIST1H1C K84ac Antibody A2055 100 µl recMAb™ Anti-CDX2 Antibody A2222 100 µg Anti-HIST1H1E K16ac Antibody A2056 100 µl Anti-CHI3L1 Antibody A2254 100 µl Anti-HIST1H1E K16me2 Antibody A2054 100 µl Anti-CK-MB Capture Antibody A2088 100 µg Anti-HIST1H1E K51ac Antibody A2051 100 µl Anti-CK-MB Detection Antibody A2089 100 µg Anti-HK1 (KO Validated) Antibody A2125 100 µl Anti-CK-MB Monoclonal Antibody A2087 100 µg Anti-HMGB1 (KO Validated) Antibody A2127 100 µl Anti-CoV-2 & SARS-CoV NP Mouse IgG1 Antibody A2066 100 µg Anti-HSPB1 (KO validated) Antibody A2074 100 µl Anti-CoV-2 & SARS-CoV NP Mouse IgG2b Antibody A2064 100 µg Anti-IFN-γ (Emapalumab), Human IgG1 Antibody A2270 100 μg Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022) A2103 200 µg Anti-IgE (Omalizumab), Humanized Antibody A2145 100 µg Anti-CoV-2, MERS & SARS-CoV NP Mouse IgG1 Antibody A2063 100 µg Anti-IGF-1R (Teprotumumab), Human IgG1 Antibody A2160 100 µg Anti-CRKL Antibody A2041 100 µl Anti-IKK-beta Antibody A2033 100 µl Anti-CTGF (Pamrevlumab), Human IgG1 Antibody A2207 100 µg Anti-IL-1β (Canakinumab), Human IgG1 Antibody A2144 100 µg Anti-CTLA-4 (Ipilimumab), Humanized Antibody A2110 100 µg Anti-IL-4Rα (Dupilumab), Human IgG4 Antibody A2148 100 µg Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibody A2163 100 µg Anti-IL5 (Mepolizumab), Humanized Antibody A2158 100 µg recMAb™ Anti-CXCR4 Antibody A2243 100 µl Anti-IL-5 (Reslizumab), Humanized Antibody A2167 100 µg Anti-CXCR6 Antibody A2042 100 µl Anti-IL-5Rα (Benralizumab), Humanized Antibody A2162 100 µg Anti-Dabigratan (Idarucizumab), Humanized Antibody A2169 100 µg Anti-IL-6 (Siltuximab), Chimeric Antibody A2143 100 µg Anti-11-Dehydro TXB2 Antibody A2165 100dtn, 500 dtn Anti-IL-6Rα (Sarilumab), Human IgG1 Antibody A2133 100 µg Anti-DHODH Antibody A2044 100 µl Anti-IL-8 Antibody A2062 100 µg Anti-Diglycyl-Lysine Antibody (Clone# GX41) A2226 100 µg Anti-IL-12β (Ustekinumab), Human IgG1 Antibody A2137 100 µg Anti-D-Dimer Detection Antibody A2090 100 µg Anti-IL-17Rα (Brodalumab), Human IgG2 Antibody A2155 100 µg Anti-D-Dimer Detection Antibody A2091 100 µg Anti-IL-17α (Ixekizumab), Humanized Antibody A2149 100 µg Anti-F9/F10 (Emicizumab), Humanized Antibody A2250 100 µg Anti-IL-17α (Netakimab), Human IgG1 Antibody A2206 100 µg Anti-FASN (KO validated) Antibody A2076 100 µl Anti-IL-17α (Secukinumab), Human IgG1 Antibody A2154 100 µg Anti-FGF21 Antibody A2036 100 µl Anti-IL-23α (Guselkumab), Human IgG1 Antibody A2147 100 µg Anti-FGF21 Antibody (Clone# ARC0865) A2237 100 µl Anti-IL23α (Mirikizumab), Humanized Antibody A2174 100 µg Anti-FGF23 Antibody (Clone# FGF23/4162) A2230 100 µg Anti-IL23α (Risankizumab), Humanized Antibody A2204 100 µg Anti-FOLR1 (Mirvetuximab), Humanized Antibody A2271 100 μg Anti-IL-23α (Tildrakizumab), Humanized Antibody A2159 100 µg recMAb™ Anti-FOXA1 Antibody A2188 100 µg Anti-ILF3 Antibody A2026 100 µl Anti-G6PD Rabbit Monoclonal Antibody A2134 100 µl Anti-Influenza A Virus Detection Antibody A2080 100 µg Anti-Galectin-3 Antibody (Clone# 3F2E2) A2232 100 µg Anti-Influenza A Virus Mouse IgG2b Capture Antibody A2083 100 µg Anti-GD2 (Naxitamab), Humanized Antibody A2273 100 μg Anti-Influenza A Virus Mouse IgG2b Detection Antibody
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al
    US 20170152273A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant et al. (43) Pub. Date: Jun. 1, 2017 (54) TOPCAL PHARMACEUTICAL Publication Classification FORMULATIONS FOR TREATING (51) Int. Cl. NFLAMMLATORY-RELATED CONDITIONS C07F 5/02 (2006.01) Applicant: A6II 47/06 (2006.01) (71) Anacor Pharmaceuticals Inc., New A69/06 (2006.01) York, NY (US) A6IR 9/00 (2006.01) (72) Inventors: Tejal Merchant, Cupertino, CA (US); A6II 47/8 (2006.01) Dina Jean Coronado, Danville, CA A6II 45/06 (2006.01) (US); Charles Edward Lee, Union A6II 47/10 (2006.01) City, CA (US); Delphine Caroline A6II 3/69 (2006.01) Imbert, Cupertino, CA (US); Sylvia (52) U.S. Cl. Zarela Yep, Milpitas, CA (US) CPC .............. C07F 5/025 (2013.01); A61K 47/10 (2013.01); A61K 47/06 (2013.01); A61K3I/69 (73) Assignee: Anacor Pharmaceuticals Inc., New (2013.01); A61K 9/0014 (2013.01); A61 K York, NY (US) 47/183 (2013.01); A61K 45/06 (2013.01); A61K 9/06 (2013.01); C07B 2.200/13 (21) Appl. No.: 15/364,347 (2013.01) (22) Filed: Nov. 30, 2016 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 62/420,987, filed on Nov. Topical pharmaceutical formulations, and methods of treat 11, 2016, provisional application No. 62/260,716. ing inflammatory conditions with these formulations, are filed on Nov. 30, 2015. disclosed. Patent Application Publication Jun. 1, 2017. Sheet 1 of 4 US 2017/0152273 A1 ?zzzzzzzzzzzzzzzzzzzzzzzzzzzz ????????????????????????????????????????????????????????????????????? S&S&S Šx&N Sssssssssssssssssssssssssssssssssssssss (r) eqn. O. peppy jeeNA go eunO/A Patent Application Publication Jun.
    [Show full text]
  • 03 November 2019 Palm Wings Ephesus Hotel Congress Center, Kus¸Adası, Aydın (Turkey)
    www.actaphysiol.org December 2019 • Volume 227 • Supplement 722 OFFICIAL JOURNAL OF THE FEDERATION OF EUROPEAN PHYSIOLOGICAL SOCIETIES Turkish Society of Physiological Sciences 45th National Physiology Congress 31 October – 03 November 2019 Palm Wings Ephesus Hotel Congress Center, Kus¸adası, Aydın (Turkey) PUBLICATION HISTORY Acta Physiologica 2006– Acta Physiologica Scandinavica 1940–2005 Skandinavisches Archiv für Physiologie 1889–1939 AAPHA_v227_is722_issue-info.inddPHA_v227_is722_issue-info.indd 1 229-Nov-199-Nov-19 12:00:2112:00:21 PMPM Chief Editor INFORMATION FOR SUBSCRIBERS Pontus B. Persson, Berlin Acta Physiologica is published in 12 issues per year. Subscription prices for 2020 € Editors are: Institutional: 1112 (Europe), $1662 (The Americas), $1942 (Rest of World). Cardiovascular Physiology – Frantisek Kolar, Prague; Holger Nilsson, Gothenburg Prices are exclusive of tax. Australian GST, Canadian GST/HST and European and William E. Louch, Oslo VAT will be applied at the appropriate rates. For more information on current tax Cell Biology – Sari Lauri, Helsinki rates, please go to www.wileyonlinelibrary.com/tax-vat. The price includes online Chronobiology and Endocrinology – Charna Dibner, Geneva access to the current and all online back fi les to January 1st 2016, where available. Exercise Physiology – Jan Henriksson, Stockholm For other pricing options, including access information and terms and conditions, Gastrointestinal Physiology – Markus Sjöblom, Uppsala please visit www.wileyonlinelibrary.com/access Infl ammation – Joakim Ek, Gothenburg Metabolism and Nutritional Physiology – Karl-Heinz Herzig, Oulu DELIVERY TERMS AND LEGAL TITLE Muscle Physiology – Gabriele Pfi tzer, Cologne Where the subscription price includes print issues and delivery is to the recipients Nervous System – Alexej Verkhratsky, Manchester address, delivery terms are Delivered at Place (DAP); the recipient is responsible Renal Physiology – Peter Bie, Odense; Boye L.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Downloaded Here
    Antibodies to Watch in a Pandemic Dr. Janice M. Reichert, Executive Director, The Antibody Society August 27, 2020 (updated slides) Agenda • US or EU approvals in 2020 • Granted as of late July 2020 • Anticipated by the end of 2020 • Overview of antibody-based COVID-19 interventions in development • Repurposed antibody-based therapeutics that treat symptoms • Newly developed anti-SARS-CoV-2 antibodies • Q&A 2 Number of first approvals for mAbs 10 12 14 16 18 20 Annual first approvals in either the US or EU or US the either in approvals first Annual 0 2 4 6 8 *Estimate based on the number actually approved and those in review as of July 15, with assumption of approval on the first c first the on of approval assumption 15, with as July of review in those and approved actually number the on based *Estimate Tables of approved mAbs and antibodies in review available at at mAbs ofand available in antibodies approved review Tables 1997 98 99 2000 01 02 03 Year of first US or EU approval or EU US of first Year 04 05 06 https://www.antibodysociety.org/resources/approved 07 08 09 10 11 12 13 14 15 Non-cancer Cancer 16 - antibodies/ 17 ycl 18 e. 19 2020* First approvals US or EU in 2020 • Teprotumumab (Tepezza): anti-IGF-1R mAb for thyroid eye disease • FDA approved on January 21 • Eptinezumab (Vyepti): anti-CGRP IgG1 for migraine prevention • FDA approved on February 21 • Isatuximab (Sarclisa): anti-CD38 IgG1 for multiple myeloma • FDA approved on March 2, also approved in the EU on June 2 • Sacituzumab govitecan (Trodelvy): anti-TROP-2 ADC for triple-neg.
    [Show full text]
  • Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Dermatology Research and Practice Volume 2012, Article ID 923134, 6 pages doi:10.1155/2012/923134 Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives Y. Valdman-Grinshpoun,1, 2 D. Ben-Amitai,1, 3 and A. Zvulunov1, 4 1 Pediatric Dermatology Unit, Schneider Children’s Medical Center of Israel, 49202 Petach Tikva, Israel 2 Department of Dermatology, Szold Health Center, Clalit Health Services, 84894 Beer-Sheva, Israel 3 Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel 4 Medical School for International Health, Faculty of Medicine, Ben-Gurion University of the Negev, 84105 Beer-Sheva, Israel Correspondence should be addressed to Y. Valdman-Grinshpoun, [email protected] Received 21 April 2012; Accepted 18 June 2012 Academic Editor: Georgios Stamatas Copyright © 2012 Y. Valdman-Grinshpoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an “itch-scratch” cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier.
    [Show full text]
  • The Comparative Enzymology and Cell Origin of Rat Hepatomas II
    The Comparative Enzymology and Cell Origin of Rat Hepatomas II. Glutamate Dehydrogenase, Choline Oxidase, and Glucose-6-phosphatase* HENRY C. PITOT~ (McArdle Memorial Laboratory, The Medical School, University of Wisconsin, Madison, Wis.) SUMMARY The activities of glucose-6-phosphatase, glutamate dehydrogcnase, and choline ox[- dase were determined in some or all of ten rat hepatomas, including the Novikoff, Dunning L-C18, McCoy MDAB, and the Morris 3683, 39524A, and 51~3 hepatomas, together with primary hepatomas produced by feeding ethionine or 3%nethyl-4- dimethylaminoazobenzene, and transplanted hepatomas derived from the primary tumors induced with ethionine. Of these neoplasms, only the Morris hepatoma 51~3, the primary and transplanted ethionine-induced hepatomas, and one of the 3'-methyl-4-dimethylaminoazobenzene- induced tumors possessed significant glucose-6-phosphatase activity. These same tu- mors in addition to the Dunning L-C18 hepatoma had demonstrable glutamate dehydro- genase activity, whereas the other neoplasms tested failed to show significant activity of this enzyme. With the exception of the primary dye-induced neoplasm, which was not tested, only those neoplasms having significant glucose-6-phosphatase activities showed any choline oxidase activity. Of those neoplasms tested for tryptophan peroxidase activity only the Morris hepa- toma 51~3, the primary ethionine-induced hepatoma, and some of the Dunning L-C18 hepatomas had any demonstrable activity of this enzyme. In contrast to most of the enzymatic activities reported here, the threonine dehydrase activity of the Morris hepatoma 51r was of the order of 40 times the level of this enzyme in the livers of animals bearing this tumor.
    [Show full text]
  • Follicle-Stimulating Hormone (FSH)
    Hormone Structure (1) Principal Source Link to diagram showing locations of the main endocrine glands Thyroid-stimulating hormone (TSH) protein (201) Follicle-stimulating hormone (FSH) protein (204) Luteinizing hormone (LH) protein (204) Anterior lobe of pituitary Prolactin (PRL) protein (198) Growth hormone (GH) protein (191) Adrenocorticotropic hormone (ACTH) peptide (39) Vasopressin peptide (9) Posterior lobe of pituitary Oxytocin peptide (9) Thyrotropin-releasing hormone (TRH) peptide (3) Gonadotropin-releasing hormone (GnRH) peptide (10) Growth hormone-releasing hormone (GHRH) peptides (40, 44) Hypothalamus Corticotropin-releasing hormone (CRH) peptide (41) Somatostatin peptides (14, 28) Dopamine tyrosine derivative Melatonin tryptophan derivative Pineal gland Thyroxine (T4) tyrosine derivative Thyroid Gland Calcitonin peptide (32) Parathyroid hormone (PTH) protein (84) Parathyroid glands FGF-23 (phosphatonin) protein (251) Osteocalcin peptide (49) Bone Lipocalin 2 protein (198) Erythropoietin (EPO) protein (166) Glucocorticoids (e.g., cortisol) steroids Mineralocorticoids (e.g., aldosterone) steroids Adrenal cortex Androgens (e.g., testosterone) steroids Adrenaline (epinephrine) tyrosine derivative Adrenal medulla Noradrenaline (norepinephrine) tyrosine derivative Estrogens (e.g., estradiol) steroid Ovarian follicle Progesterone steroid Corpus luteum and placenta Human chorionic gonadotropin (HCG) protein (237) Trophoblast and placenta Androgens (e.g., testosterone) steroid Testes Insulin protein (51) Glucagon peptide (29) Pancreas
    [Show full text]
  • Western Blot Sandwich ELISA Immunohistochemistry
    $$ 250 - 150 - 100 - 75 - 50 - 37 - Western Blot 25 - 20 - 15 - 10 - 1.4 1.2 1 0.8 0.6 OD 450 0.4 Sandwich ELISA 0.2 0 0.01 0.1 1 10 100 1000 Recombinant Protein Concentration(mg/ml) Immunohistochemistry Immunofluorescence 1 2 3 250 - 150 - 100 - 75 - 50 - Immunoprecipitation 37 - 25 - 20 - 15 - 100 80 60 % of Max 40 Flow Cytometry 20 0 3 4 5 0 102 10 10 10 www.abnova.com June 2013 (Fourth Edition) 37 38 53 Cat. Num. Product Name Cat. Num. Product Name MAB5411 A1/A2 monoclonal antibody, clone Z2A MAB3882 Adenovirus type 6 monoclonal antibody, clone 143 MAB0794 A1BG monoclonal antibody, clone 54B12 H00000126-D01 ADH1C MaxPab rabbit polyclonal antibody (D01) H00000002-D01 A2M MaxPab rabbit polyclonal antibody (D01) H00000127-D01 ADH4 MaxPab rabbit polyclonal antibody (D01) MAB0759 A2M monoclonal antibody, clone 3D1 H00000131-D01 ADH7 MaxPab rabbit polyclonal antibody (D01) MAB0758 A2M monoclonal antibody, clone 9A3 PAB0005 ADIPOQ polyclonal antibody H00051166-D01 AADAT MaxPab rabbit polyclonal antibody (D01) PAB0006 Adipoq polyclonal antibody H00000016-D01 AARS MaxPab rabbit polyclonal antibody (D01) PAB5030 ADIPOQ polyclonal antibody MAB8772 ABCA1 monoclonal antibody, clone AB.H10 PAB5031 ADIPOQ polyclonal antibody MAB8291 ABCA1 monoclonal antibody, clone AB1.G6 PAB5069 Adipoq polyclonal antibody MAB3345 ABCB1 monoclonal antibody, clone MRK16 PAB5070 Adipoq polyclonal antibody MAB3389 ABCC1 monoclonal antibody, clone QCRL-2 PAB5124 Adipoq polyclonal antibody MAB5157 ABCC1 monoclonal antibody, clone QCRL-3 PAB9125 ADIPOQ polyclonal antibody
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0235763 A1 Budunova Et Al
    US 2016O235763A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0235763 A1 BudunOVa et al. (43) Pub. Date: Aug. 18, 2016 (54) USE OF REDD1 INHIBITORSTO Publication Classification DISSOCATE THERAPEUTIC AND ADVERSE ATROPHOGENCEFFECTS OF (51) Int. Cl. GLUCOCORTICOD RECEPTORAGONSTS A613 L/56 (2006.01) A613 L/713 (2006.01) (71) Applicant: Northwestern University, Evanston, IL A613 L/436 (2006.01) (US) (52) U.S. Cl. CPC ............... A61 K3I/56 (2013.01); A61 K3I/436 (72) Inventors: Irina Budunova, Chicago, IL (US); (2013.01); A61 K3I/713 (2013.01) Gleb Baida, Chicago, IL (US); Joel Dudley, Rye, NY (US) (57) ABSTRACT (73) Assignee: Northwestern University, Evanston, IL (US) Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with (21) Appl. No.: 15/046,075 glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a (22) Filed: Feb. 17, 2016 patient in need thereofaglucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 Related U.S. Application Data inhibitor that inhibits expression or activity of REDD1, (60) Provisional application No. 62/117,248, filed on Feb. wherein the REDD1 inhibitor is administered before, concur 17, 2015. rently with, or after the GRagonist is administered. Patent Application Publication Aug. 18, 2016 Sheet 1 of 17 US 2016/0235763 A1 Figre s: S. 48 :383.3 ge is: 8xx xx & s SS s sa a:23 8x3: & 25 88: c s S: 3 3 : 88 s : 3. s 3 : 3S s is $8 3S. .'ss& 3S citos. 8d.: Patent Application Publication Aug.
    [Show full text]
  • The Impaired Response of Circulating Asprosin Concentrations to Glucose Levels Fluctuation May Be One of the Causes of Type 2 Diabetes – a Narrative Review
    Trojanowska Paulina, Trojanowska Alina, Szydełko Joanna, Tywanek Ewa, Łuczyk Robert Jan. The impaired response of circulating asprosin concentrations to glucose levels fluctuation may be one of the causes of type 2 diabetes – a narrative review. Journal of Education, Health and Sport. 2020;10(9):846-854. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.09.10 2 https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/JEHS.2020.10.09. 10 2 https://zenodo.org/record/4054287 The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019. © The Authors 2020; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 21.09.2020. Revised: 27.09.2020. Accepted: 28.09.2020. The impaired response of circulating asprosin concentrations
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Complementopathies and Precision Medicine
    Complementopathies and precision medicine Eleni Gavriilaki, Robert A. Brodsky J Clin Invest. 2020;130(5):2152-2163. https://doi.org/10.1172/JCI136094. Review The renaissance of complement diagnostics and therapeutics has introduced precision medicine into a widened field of complement-mediated diseases. In particular, complement-mediated diseases (or complementopathies) with ongoing or published clinical trials of complement inhibitors include paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, hemolytic uremic syndrome, nephropathies, HELLP syndrome, transplant-associated thrombotic microangiopathy, antiphospholipid antibody syndrome, myasthenia gravis, and neuromyelitis optica. Recognizing that this field is rapidly expanding, we aim to provide a state-of-the-art review of (a) current understanding of complement biology for the clinician, (b) novel insights into complement with potential applicability to clinical practice, (c) complement in disease across various disciplines (hematology, nephrology, obstetrics, transplantation, rheumatology, and neurology), and (d) the potential future of precision medicine. Better understanding of complement diagnostics and therapeutics will not only facilitate physicians treating patients in clinical practice but also provide the basis for future research toward precision medicine in this field. Find the latest version: https://jci.me/136094/pdf REVIEW The Journal of Clinical Investigation Complementopathies and precision medicine Eleni Gavriilaki1 and Robert A. Brodsky2 1Hematology Department,
    [Show full text]